Ergebnis der Suchanfrage nach Marke Invasion
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Johnson & Johnson Biosense Webster
Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform
Irvine, Calif. (ots/PRNewswire) - - Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. - Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ...
mehrJapan International Cooperation Agency (JICA) commits $20 million to Horizon Capital Growth Fund IV (HCGF IV), marking firm's first Japanese backer
Tokyo (ots/PRNewswire) - Horizon Capital, a U.S. private-equity firm with $1.6 billion AUM investing primarily in fast-growing tech and export-oriented companies in Ukraine, announced that its latest fund, HCGF IV has accepted a $20 million commitment from JICA. The investment was announced during the ...
mehrIntuitive Surgical Deutschland GmbH
Intuitive’s da Vinci Single-Port Surgical System Receives CE Mark / da Vinci SP approved for use in Europe across multiple procedures
Sunnyvale, Calif. (ots) - Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that the da Vinci Single-Port (SP) surgical system has received CE mark approval for use in Europe for endoscopic abdominopelvic, thoracoscopic, transoral ...
mehrWestern NIS Enterprise Fund (WNISEF)
u.ventures Invests Record $4M in Eight Ukrainian and One Moldovan Startup Since Russia's Full-Scale Invasion
Kyiv, Ukraine (ots/PRNewswire) - u.ventures, a leading venture capital fund based in Kyiv, Ukraine, has invested $4 million in eight promising Ukrainian and one Moldovan startup since Russia's full-scale invasion began on February 24, 2022. This marks a significant commitment to Ukraine's resilient tech sector amid ...
mehrIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...
mehrDeep Breath Intelligence Teams with HTEC Group and Effectum Medical to Accelerate the Launch of CE-marked device under IVDD
Belgrade, Serbia (ots/PRNewswire) - Deep Breath Intelligence (DBI), a MedTech company unleashing the huge potential of exhaled breath analysis through machine learning, has selected HTEC Group and Effectum Medical as primary innovation facilitators to help them achieve greater speed in meeting both software and ...
mehr/C O R R E C T I O N -- Croma-Pharma/
Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...
mehrCroma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter
Vienna (ots/PRNewswire) - - Company reports strong financial results for 2022 with 27% revenue growth in 2022 and significantly increased margins - Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as well as strong market growth - Continued market share gains, strategic mid-term ...
mehrPM: DHL: Mehr als 60.000 Hilfspakete in die Ukraine befördert / PR: DHL: More than 60,000 care packages shipped to Ukraine
mehrSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
mehrSysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...
mehrNTT DATA Business Solutions AG
itelligence project wins SAP Innovation Award in "Process Innovator" category / Innovative Environmental Protection Project of itelligence AG Honored by SAP
Orlando/Bielefeld (ots) - itelligence has won an SAP Innovation Award in the "Process Innovator" category with a project involving the use of drones and image recognition for the purposes of environmental protection. These awards honor companies that operate successfully in the digital economy making use of SAP ...
mehr